Ketoprofen transdermal - IDEA AG

Drug Profile

Ketoprofen transdermal - IDEA AG

Alternative Names: Diractin; IDEA-033

Latest Information Update: 26 Mar 2015

Price : $50

At a glance

  • Originator IDEA
  • Developer Alpharma; IDEA
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Musculoskeletal pain; Pain

Most Recent Events

  • 31 Dec 2008 Alpharma has been acquired by King Pharmaceuticals
  • 24 Jul 2008 IDEA AG withdraws an MAA with the EMEA for Musculoskeletal pain
  • 10 Feb 2008 Phase-III clinical trials in Musculoskeletal pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top